On Thursday, September 16, 2021, African genomics research startup 54gene, announced a $25 million Series B round.
The funding will be used to expand the startup’s sequencing, target identification and validation, and precision medicine clinical trial capabilities, enabling drug discovery in Africa for Africans and the world.Advertisement
Cathay AfricInvest Innovation Fund led the round. Existing investors like Adjuvant Capital, KdT Ventures, Plexo Capital, Endeavor Capital, and Ingressive Capital participated in the round.
Launched in 2019 by Dr Abasi Ene-Obong (CEO), 54gene is a healthtech company centred around unlocking scientific discoveries and enhancing diagnosis and treatment outcomes across Africa and the rest of the world. Continue reading
Image: techpoint.africa